{"url_path":"/sec/mira/8-k/2026-06-17/item-7-01","section_key":"item-7-01","section_title":"Item 7.01 Regulation FD Disclosure.**","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-17","source_url":"https://www.sec.gov/Archives/edgar/data/1904286/0001493152-26-028992-index.html","accession_number":"0001493152-26-028992","cik":"0001904286","ticker":"MIRA","issuer_name":"MIRA PHARMACEUTICALS, INC.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1904286/0001493152-26-028992-index.html","primary_entity_key":"0001904286","primary_entity_name":"MIRA PHARMACEUTICALS, INC."},"word_count":194,"has_tables":true,"body_markdown":"**Item\n7.01 Regulation FD Disclosure.**\n\n \n\nOn\nJune 17, 2026, MIRA Pharmaceuticals, Inc. (the “Company”) issued a press release announcing the submission of a Phase 2a\nclinical trial protocol to the U.S. Food and Drug Administration (FDA) for Ketamir-2, the Company’s proprietary oral NMDA receptor\nmodulator, in chemotherapy-induced peripheral neuropathy (CIPN). A copy of the press release is attached hereto as Exhibit 99.1 and incorporated\nherein by reference.\n\n \n\nIn\nconnection with the submission, the Company received an acknowledgment of receipt from the FDA confirming acceptance of the Phase 2a\nclinical trial protocol submission for Protocol Mira-002. A copy of the FDA submission receipt is attached hereto as Exhibit 99.2 and\nincorporated herein by reference.\n\n \n\nThe\ninformation in this Item 7.01, including Exhibit 99.1 and Exhibit 99.2, is being furnished and shall not be deemed “filed”\nfor purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject\nto the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933,\nas amended, or the Exchange Act, except as expressly set forth by specific reference in such filing."}